Foster City News
-
Gilead Sciences Inc., which fueled a land grab for hepatitis C therapies with its $10.8 billion purchase last year of Pharmasset Inc., dropped the most in 11 years after some patients on the acquired experimental medicine relapsed after stopping therapy.
-
Shares of the following companies had unusual moves in U.S. trading. Stock symbols are in parentheses and prices are as of 4 p.m. in New York.
-
Actelion Ltd., the Swiss maker of the Tracleer lung treatment, aims for profit this year to be unchanged as the economic crisis puts pressure on drug prices and the company loses market share to Gilead Sciences Inc.
-
Gilead Sciences Inc., the drugmaker that acquired Pharmasset Inc. last month for its experimental hepatitis C treatments, gained the most in three years after one of the medicines produced positive clinical trial results.
-
Actelion Ltd. Chief Executive Officer Jean-Paul Clozel has staked the future of the company he founded on an experimental drug that analysts say has a 63 percent chance of success.
-
Biogen Idec Inc. may ultimately join Amgen Inc. as biotechnology companies that pay a dividend, Chief Financial Officer Paul Clancy said.
-
Combining two experimental Bristol- Myers Squibb Co. pills cleared the hepatitis C virus in 36 percent of patients not helped by a standard treatment, in a small study testing a new approach against the liver disease.
-
Bristol-Myers Squibb Co. agreed to pay about $2.5 billion in cash to buy Inhibitex Inc., the second maker of hepatitis C drugs to be acquired within two months as companies jockey for position in a developing $20 billion market.
-
Europe’s largest drugmakers may step up acquisitions of biotechnology companies this year after spending money in 2011 on stock buybacks and higher dividends to keep shareholders happy.
-
Bristol-Myers Squibb Co., the drugmaker that will lose patent protection for three of its top four drugs within three years, will follow its $2.5 billion Inhibitex Inc. purchase with more deals as the company’s “string of pearls” acquisition strategy begins to pay off.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page